SCM
ENTA icon

Soleus Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Soleus Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-785,546
Closed -$8.14M – 93
2024
Q3 		$8.14M Sell
785,546
-14,000
-2% -$183K 0.63% 42
2024
Q2 		$10.4M Buy
799,546
+219,000
+38% +$2.96M 0.91% 35
2024
Q1 		$10.1M Buy
+580,546
New +$7.68M 0.75% 39
2023
Q2 		– Sell
-116,514
Closed -$4.71M – 102
2023
Q1 		$4.71M Sell
116,514
-21,300
-15% -$1.02M 0.49% 52
2022
Q4 		$6.41M Buy
137,814
+14,800
+12% +$675K 0.92% 32
2022
Q3 		$6.38M Buy
123,014
+23,014
+23% +$1.34M 0.87% 36
2022
Q2 		$4.73M Sell
100,000
-102,485
-51% -$5.56M 0.74% 41
2022
Q1 		$14.4M Sell
202,485
-115,790
-36% -$7.53M 1.86% 19
2021
Q4 		$23.8M Buy
318,275
+135,875
+74% +$10.7M 2.38% 9
2021
Q3 		$10.4M Buy
+182,400
New +$9.02M 1.61% 17
2020
Q4 		– Sell
-11,500
Closed -$526K – 71
2020
Q3 		$526K Hold
11,500
– – 0.28% 54
2020
Q2 		$577K Buy
11,500
+900
+8% +$46.6K 0.33% 53
2020
Q1 		$545K Buy
+10,600
New +$565K 0.63% 32

Other funds holding ENTA

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Soleus Capital Management's ENTA Position: Q4 2024 in Review

Soleus Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2024, closing a stake of 785,546 shares — an estimated $8.14M sold.

Soleus Capital Management first reported a position in ENTA in Q1 2020 and held it in 13 quarters. The position peaked at $23.8M in Q4 2021. 107 funds tracked by Wall St. Rank hold ENTA as of Q4 2024.

  • Soleus Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Soleus Capital Management sold 785,546 Enanta Pharmaceuticals shares in Q4 2024, an estimated $8.14M.
  • Soleus Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2020 and held it in 13 quarters.
  • Soleus Capital Management's Enanta Pharmaceuticals position peaked at $23.8M in Q4 2021.
  • 107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2024.

Based on Soleus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.